Monitoring of Donor-specific Antibodies After Treatment with Immunoglobulins, Plasmapheresis and Rituximab in Lung Transplantation
- Conditions
- Lung TransplantationDonor-specific Anti-human Leukocyte Antigen(HLA) Antibodies
- Registration Number
- NCT03798860
- Lead Sponsor
- Hannover Medical School
- Brief Summary
Single-arm, prospective observational study
- Detailed Description
This is an observational study to monitor the treatment of donor-specific antibodies in lung transplant recipients with detection of donor-specific antibodies. All consented subjects will be approached for participation. The study will evaluate the effectiveness of the treatment protocol of donor-specific antibodies with Immunoglobulins or combined treatment with Immunoglobulins, Plasmapheresis and Rituximab after lung transplantation.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- All
- Target Recruitment
- 75
- all patients after lung transplantation with detection of donor-specific antibodies
- none
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Donor-specific Antibodies Clearance 6, 12, 18, 24 months The DSA clearance is defined as absence of DSA in the Luminex test, which is performed every 6 months after treatment end.
- Secondary Outcome Measures
Name Time Method Graft survival 1, 3, 5 years Graft survival is defined as freedom from mortality and re-transplantation
Incidence of acute cellular and humoral rejections and chronic lung allograft dysfunction (CLAD) 1, 3, 5 years
Trial Locations
- Locations (1)
Hannover Medical School, Department of Cardiothoracic, Transplant and Vascular Surgery
🇩🇪Hannover, Germany